This randomized, multicenter, double-blind, parallel group study will evaluate the impact of methotrexate discontinuation on the efficacy of subcutaneous RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to current methotrexate therapy. Patients will be initiated on RoActemra/Actemra 162 mg weekly or every 2 weeks, remaining on a stable dose of methotrexate. At Week 24, patients achieving a disease activity score (DAS28) </=3.2 will be randomized to either continue receiving a stable dose of methotrexate or to switch to matching placebo until Week 52.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01855789?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
